A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Taxotere (Docetaxel) in the Treatment of Subjects With Solid Tumors.

Trial Profile

A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Taxotere (Docetaxel) in the Treatment of Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Navitoclax (Primary) ; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 21 May 2012 Actual patient number changed from 50 to 41 as reported by ClinicalTrials.gov.
    • 21 May 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
    • 21 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top